Webinars and Presentations

Odylia Gene Therapy Program Updates

February 2022: Several key milestones for the RPGRIP1 Program were achieved in 2021. Odylia Therapeutics will present a summary of those benchmarks and what it means for the program. We’ll also discuss the plans for 2022 to continue to move the program forward, timelines, and the resources needed. Follow the link to register for Odylia’s next update on the RPGRIP1 Gene Therapy Program.

September 2021: Odylia Therapeutics CSO, Ashley Winslow, and Director of Development, Heather Greene, discuss Odylia’s RPGRIP1 Gene Therapy program to treat vision loss in patients diagnosed with Leber Congenital Amaurosis 6 (LCA6). Follow the link to view a recording of the webinar.

Odylia Therapeutics & Foundation Fighting Blindness Preclinical and Translational Webinar Series

Sponsored by Regeneron

Webinar #1: Tools for Preclinical Development: Creating a Target Product Profile and Effectively Engaging Regulatory Entities (October 2020)

Webinar #2: Disease relevant translation models in ocular drug development: Types, challenges, advantages, and alternatives

Webinar #3: Working with Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) to accelerate development (January 2021)

Webinar #4: Attracting funding opportunities and a look towards the future of ocular drug development (March 2021)

Conference Presentations

The challenges of bringing gene therapy treatments for rare disease to clinical trial, World Orphan Drug Congress Europe 2020, Scott Dorfman, CEO

Exploring Innovative Partnerships to Enable Gene Therapy Manufacturing for Rare Ocular Disorders, Gene Therapy for Ophthalmic Disorders 2020- Ashley Winslow, CSO

PANEL DISCUSSION: Evaluating the Current Commercial Landscape in Light of a Recent Ophthalmic Approval, Gene Therapy for Ophthalmic Disorders 2020- Ashley Winslow, CSO

Sharing Insight for Gene Therapy Manufacturing, The NIH and FDA Workshop on Expanding AAV Manufacturing Capacity for Rare Disease Gene Therapies, Scott Dorfman, CEO

Questions? We’re here to help!